Ken Griffin Inhibrx, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $2.45 Million - $2.96 Million	-74,700 Reduced 77.01%	22,300 $779,000
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $1.36 Million - $3.58 Million	94,100 Added 3244.83%	97,000 $3.69 Million
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $11,025 - $18,417	-700 Reduced 19.44%	2,900 $53,000
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $39,008 - $63,986	-2,300 Reduced 38.98%	3,600 $93,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $51,660 - $75,992	-2,800 Reduced 32.18%	5,900 $111,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $175,566 - $289,971	8,700 New	8,700 $214,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $625M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.